
    
      The primary objective is to compare Overall Survival (OS) of participants with Stage
      IV/recurrent NSCLC of squamous histology who have been randomized to ipilimumab in addition
      to paclitaxel and carboplatin versus placebo in addition to paclitaxel and carboplatin, and
      have received at least one dose of blinded study therapy (ipilimumab or placebo).
    
  